Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Mylan | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Mylan

Revenues up 16% in the quarter boosted by European third party sales and acquisitions of Meda and Topicals Business

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mylan
2Q Revenues: $3.0 billion (+16%)
2Q Earnings: $297 million (+77%)
YTD Revenues: $5.7 billion (+20%)
YTD earnings: $363 million (+99%)
Comments: North America segment third party sales were $1.3 billion, down 9%, with sales of EpiPen Auto-Injector down by approximately $172 million as a result of increased competition, the impact of the launch of the authorized generic and higher accrued governmental rebates. Europe segment third party net sales of $954.3 million, up 59%. Rest of World segment third party net sales of $692.6 million, up 29%. Net sales from the acquisitions of Meda and the Topicals Business totaled approximately $150.7 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters